Drug Discovery World
FEBRUARY 22, 2024
With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.
Drug Discovery World
OCTOBER 4, 2022
New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 23, 2023
Clinical trials revealed eight out of nine predictions were correct. In the months and years that followed our screens to rapidly identify repurposable treatments for Covid-19, we watched closely as our predictions made their way through clinical studies and into patients.
Drug Discovery World
JANUARY 26, 2023
The modernisation of R&D models could be key to reducing spend on new drugs, a point that Deloitte makes about the need to transform the clinical trials process. At the height of the pandemic, DCTs were seen as a viable alternative to keeping the engines running on clinical trials when non-critical in-person care was paused.
Drug Discovery World
AUGUST 15, 2023
Consequently, electrophysiological techniques need to be developed that can provide better translation from small mammalian hearts into larger hearts and then on into human clinical trials. Figure 3: Electrograms (left panel) are recorded at increasingly short intervals between the stimuli (the ‘S1S2 interval’).
Expert insights. Personalized for you.
52 
Let's personalize your content